Mycosis fungoides and Sézary syndrome following dupilumab treatment: experience of two Italian tertiary care centres
Stefano Buffon, Silvia Alberti Violetti, Gianluca Avallone, Luigia Venegoni, Angelo Valerio Marzano, Luca Mastorino, Paolo Fava, Simone Ribero, Pietro Quaglino, Michela Ortoncelli, Silvia Mariel Ferrucci
Abstract
Dupilumab is a monoclonal antibody targeting the interleukin-4 and -13 signalling pathway, and which is proven to be highly effective and safe in atopic dermatitis (AD). Its possible role in treating or inducing cutaneous T-cell lymphomas (CTCLs) has not yet been fully clarified, as several case reports seem to point not only at its beneficial effects but also at a possible pathogenetic role in mycosis fungoides and Sézary syndrome. We present data collected from a cohort of 995 patients with classic or prurigo nodularis-like AD who received dupilumab and were followed longitudinally for a mean period of 25.1 months after first administration to investigate a possible correlation between dupilumab and CTCL development.